ERBB2 and breast cancer: Intrinsic subtypes were grouped in the NonMet-BC and Met-BC groups, respectively, as follows: 7 (16.7%) and 16 (21.6%) were identified as Luminal A, 20 (47.6%) and 26 (35.1%) as Luminal B-HER2 negative, 6 (14.3%) and 4 (5.4%) as Luminal B-HER2 positive, 5 (14.3%) and 15 (20.3%) as triple-negative tumors, and 3 (7.1%) and 13 (17.6%) as HER2 enriched.